Robert Cerwinski, JD, Partner at Goodwin, discusses the potential for an upcoming executive order on drug pricing.
Transcript:
Can we expect to see an executive order on drug pricing in the coming months?
You know, I think the executive branch is a little bit at odds with itself. We are not really sure from one day to the next what the priorities are going to be, and with all of the debate right now over Obamacare, I really cannot say that we can predict that with any degree of certainty. I think all that we can predict, when it comes to healthcare, is that the executive branch is going to continue to surprise us.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.